Alteplase

Generic Name: Alteplase

Brand Names: Activase, Cathflo, Cathflo Activase

Drug Type: Biotech

Chemical Formula: -

CAS Number: 105857-23-6

Unique Ingredient Identifier: 1RXS4UE564

Background: Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...

Indication: Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...

Associated Conditions: Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis

Associated Therapies: -

Clinical Trials

Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

Phase 1

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: chlorpromazine and promethazine
Drug: Placebo group
Procedure: endovascular thrombectomy
Drug: rt-PA

First Posted Date: 2024-10-29

Last Posted Date: 2024-12-20

Lead Sponsor: Capital Medical University

Target Recruit Count: 32

Registration Number: NCT06663631

Locations: 🇨🇳
Linyi People's Hospital, Linyi, Shandong, China

Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke

Phase 3

Not yet recruiting

Conditions: Stroke, Ischemic
Stroke, Acute
Thrombosis, Brain
Drug Effect

Interventions: Drug: Tenecteplase
Drug: Alteplase

First Posted Date: 2024-10-26

Last Posted Date: 2024-10-26

Lead Sponsor: Xuanwu Hospital, Beijing

Target Recruit Count: 850

Registration Number: NCT06658197

Locations: 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China

the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Phase 4

Recruiting

Conditions: Ischemic Stroke
Alteplase Adverse Reaction

Interventions: Drug: Alteplase

First Posted Date: 2024-10-23

Last Posted Date: 2024-10-29

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 716

Registration Number: NCT06653946

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction

Phase 4

Recruiting

Conditions: Ischemic Stroke
Alteplase Adverse Reaction

Interventions: Drug: Alteplase

First Posted Date: 2024-03-29

Last Posted Date: 2024-03-29

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 600

Registration Number: NCT06337175

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: Urokinase
Drug: Alteplase

First Posted Date: 2024-01-08

Last Posted Date: 2024-01-08

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 1800

Registration Number: NCT06194968

Locations: 🇨🇳
Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
🇨🇳
Red Cross Hospital of Yulin City, Yulin, Guangxi, China
🇨🇳
The First People's Hospital of Yulin, Yulin, Guangxi, China

and more 13 locations

ALteplase in Patients With LOW NIHSS and Specified Disabling Deficits

Phase 4

Recruiting

Conditions: Thrombosis

Interventions: Drug: Alteplase

First Posted Date: 2023-11-02

Last Posted Date: 2024-03-18

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 300

Registration Number: NCT06115070

Locations: 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China

Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase
Drug: Alteplase

First Posted Date: 2023-10-12

Last Posted Date: 2023-10-12

Lead Sponsor: Huashan Hospital

Target Recruit Count: 1200

Registration Number: NCT06078995

Locations: 🇨🇳
Xin Chen, Shanghai, China

Predictors of AIS Unfavorable Outcomes

Phase 4

Completed

Conditions: Ischemic Stroke
Alteplase Adverse Reaction

Interventions: Drug: Alteplase

First Posted Date: 2023-09-28

Last Posted Date: 2023-10-10

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 592

Registration Number: NCT06058884

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

Phase 4

Not yet recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Aspirin
Drug: Alteplase
Drug: Clopidogrel

First Posted Date: 2023-06-18

Last Posted Date: 2023-06-18

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 472

Registration Number: NCT05910125

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy

Phase 3

Recruiting

Conditions: Stroke, Acute Ischemic

Interventions: Drug: Alteplase

First Posted Date: 2023-05-12

Last Posted Date: 2023-08-14

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 324

Registration Number: NCT05856851

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy